Anthony J. Blasquez, Executive Vice President at Upbound Group, Inc. (NASDAQ:UPBD), filed a Form 4 on August 26, 2026, reporting the sale of 10,000 shares of common stock on August 21, 2026.
Anthony Li Hsieh, Executive Chair, CEO, and President of loanDepot, Inc. (NYSE:LDI), filed a Form 4 on August 26, 2026, disclosing open-market purchases of Class A Common Stock on August 24 and August 25, 2026, through the JLSSAA Trust.
Ernest S. Rady, Executive Chairman of American Assets Trust, Inc., filed a Form 4 on August 26, 2026, disclosing two open-market purchases of common stock made on August 24 and August 26, 2026.
A Form 4 filed on August 26, 2026, reports that Justin Rounce, Executive Vice President and Chief Technology Officer of TechnipFMC plc (NYSE:FTI), had 118,843 ordinary shares withheld on August 25, 2026, to cover taxes on vested performance stock units.
Alf Melin, Executive Vice President and Chief Financial Officer of TechnipFMC plc, filed a Form 4 on August 26, 2026, disclosing the disposition of ordinary shares withheld to cover taxes on vested performance stock units.
A Form 4 filed on August 26, 2026, with the SEC reports that Ernst W. Bruderer, a director of CoastalSouth Bancshares, Inc. (NASDAQ:COSO), sold 2,000 shares of common stock on August 26, 2026.
Douglas J. Pferdehirt, Chair and CEO of TechnipFMC plc (NYSE:FTI), filed a Form 4 on August 26, 2026, reporting the withholding of ordinary shares to cover taxes on vested performance stock units.
Ernie J. Garateix, Chief Executive Officer and Director of Heritage Insurance Holdings, Inc. (NYSE:HRTG), filed a Form 4 on August 26, 2026, reporting the sale of 10,000 shares of common stock on August 24, 2026.
Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, Inc., filed a Form 4 on August 26, 2026, disclosing the sale of 50,160 shares of common stock across three transactions on August 24 and August 25, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Abraham Ceesay, Chief Executive Officer and Director of Rapport Therapeutics, Inc. (NASDAQ:RAPP), filed a Form 4 on August 26, 2026, disclosing the sale of 18,921 shares of common stock on August 25, 2026.